Amgen (AMGN)

Executive Summary

Amgen is a global biotechnology leader with a $189B market cap, specializing in innovative biologic medicines across cardiovascular, oncology, bone health, and inflammation. The company's commercial portfolio includes blockbusters like Repatha (evolocumab), Prolia (denosumab), and Enbrel (etanercept), which provide stable cash flows. Amgen is investing heavily in next-generation modalities, including bispecific T-cell engagers, siRNA therapeutics, and obesity treatments. Key growth drivers include the obesity candidate AMG 133 (MariTide), which is in Phase 2 with promising early data, and IMDELLTRA (tarlatamab) for small cell lung cancer, which recently received accelerated approval. Additionally, the company's biosimilar pipeline and early-stage assets in cardiovascular disease (e.g., olpasiran, an Lp(a) inhibitor) offer long-term potential. Despite headwinds from patent expirations and pricing pressures, Amgen's diversified pipeline and strong execution support a positive outlook.

Upcoming Catalysts (preview)

• Q4 2026MariTide (AMG 133) Phase 2 obesity data update70% success
• Q1 2027IMDELLTRA (tarlatamab) FDA decision for first-line SCLC60% success
• H2 2027Olpasiran (Lp(a) inhibitor) Phase 3 cardiovascular outcomes top-line results65% success